Connection
Jeffrey Goldstein to Cytochrome P-450 CYP2C9
This is a "connection" page, showing publications Jeffrey Goldstein has written about Cytochrome P-450 CYP2C9.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.154 |
|
|
|
-
Goldstein JA, Blaisdell JA, Limdi NA. A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy. Blood Cells Mol Dis. 2009 Mar-Apr; 42(2):155-8.
Score: 0.082
-
Ibeanu GC, Goldstein JA. Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions. Biochemistry. 1995 Jun 27; 34(25):8028-36.
Score: 0.032
-
Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis. 2009 Jul-Aug; 43(1):119-28.
Score: 0.021
-
Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2008 Feb; 83(2):312-21.
Score: 0.019